Back to Search Start Over

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Authors :
Polverelli N
Farina M
D'Adda M
Damiani E
Grazioli L
Leoni A
Malagola M
Bernardi S
Russo D
Source :
Cells [Cells] 2022 Feb 05; Vol. 11 (3). Date of Electronic Publication: 2022 Feb 05.
Publication Year :
2022

Abstract

Moving from indication to transplantation is a critical process in myelofibrosis. Most of guidelines specifically focus on either myelofibrosis disease or transplant procedure, and, currently, no distinct indication for the management of MF candidates to transplant is available. Nevertheless, this period of time is crucial for the transplant outcome because engraftment, non-relapse mortality, and relapse incidence are greatly dependent upon the pre-transplant management. Based on these premises, in this review, we will go through the path of identification of the MF patients suitable for a transplant, by using disease-specific prognostic scores, and the evaluation of eligibility for a transplant, based on performance, comorbidity, and other combined tools. Then, we will focus on the process of donor and conditioning regimens' choice. The pre-transplant management of splenomegaly and constitutional symptoms, cytopenias, iron overload and transplant timing will be comprehensively discussed. The principal aim of this review is, therefore, to give a practical guidance for managing MF patients who are potential candidates for allo-HCT.

Details

Language :
English
ISSN :
2073-4409
Volume :
11
Issue :
3
Database :
MEDLINE
Journal :
Cells
Publication Type :
Academic Journal
Accession number :
35159362
Full Text :
https://doi.org/10.3390/cells11030553